Vertex Pharmaceuticals Earnings Estimate

VRTX Stock

USD 422.00 5.04 1.21%

The next projected EPS of Vertex Pharmaceuticals is estimated to be 0.1305 with future projections ranging from a low of 0.0125 to a high of 0.355. Vertex Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -1.91. Please be aware that the consensus of earnings estimates for Vertex Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Vertex Pharmaceuticals is projected to generate 0.1305 in earnings per share on the 31st of December 2024. Vertex Pharmaceuticals earnings estimates show analyst consensus about projected Vertex Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Vertex Pharmaceuticals' historical volatility. Many public companies, such as Vertex Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Vertex Pharmaceuticals' earnings estimates, investors can diagnose different trends across Vertex Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit is likely to rise to about 10.4 B in 2025. Pretax Profit Margin is likely to rise to 0.42 in 2025

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

Vertex Pharmaceuticals Earnings Estimation Breakdown

The calculation of Vertex Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vertex Pharmaceuticals is estimated to be 0.1305 with the future projection ranging from a low of 0.0125 to a high of 0.355. Please be aware that this consensus of annual earnings estimates for Vertex Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.

Last Reported EPS

4.38

0.01

Lowest

Expected EPS

0.1305

0.35

Highest

Vertex Pharmaceuticals Earnings Projection Consensus

Suppose the current estimates of Vertex Pharmaceuticals' value are higher than the current market price of the Vertex Pharmaceuticals stock. In this case, investors may conclude that Vertex Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vertex Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.

Number of Analysts	Historical Accuracy	Last Reported EPS		Estimated EPS for 31st of December 2024	Current EPS (TTM)
35	83.07%	4.38		0.1305	-1.91

Vertex Pharmaceuticals Earnings per Share Projection vs Actual

Actual Earning per Share of Vertex Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vertex Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Vertex Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Vertex Pharmaceuticals Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Vertex Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vertex Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.

Vertex Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Vertex Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.

Reported	Fiscal Date	Estimated EPS	Reported EPS	Surprise
2024-11-04	2024-09-30	4.14	4.38	0.24	5
2024-08-01	2024-06-30	2.94	-12.83	-15.77	536
2024-05-06	2024-03-31	4.06	4.76	0.7	17
2024-02-05	2023-12-31	4.1	4.2	0.1	2
2023-11-06	2023-09-30	3.97	4.08	0.11	2
2023-08-01	2023-06-30	3.88	3.89	0.01	0
2023-05-01	2023-03-31	3	3.05	0.05	1
2023-02-07	2022-12-31	3.51	3.76	0.25	7
2022-10-27	2022-09-30	3.64	4.01	0.37	10
2022-08-04	2022-06-30	3.48	3.6	0.12	3
2022-05-05	2022-03-31	3.49	3.52	0.03	0
2022-01-26	2021-12-31	3.3	3.37	0.07	2
2021-11-02	2021-09-30	3.08	3.56	0.48	15
2021-07-29	2021-06-30	2.51	3.11	0.6	23
2021-04-29	2021-03-31	2.69	2.98	0.29	10
2021-02-01	2020-12-31	2.59	2.51	-0.08	3
2020-10-29	2020-09-30	2.34	2.64	0.3	12
2020-07-30	2020-06-30	2.07	2.61	0.54	26
2020-04-29	2020-03-31	1.85	2.56	0.71	38
2020-01-30	2019-12-31	1.21	1.7	0.49	40
2019-10-30	2019-09-30	1.15	1.23	0.08	6
2019-07-31	2019-06-30	1.07	1.26	0.19	17
2019-04-30	2019-03-31	0.97	1.14	0.17	17
2019-02-05	2018-12-31	1.06	1.3	0.24	22
2018-10-24	2018-09-30	1.02	1.09	0.07	6
2018-07-25	2018-06-30	0.75	0.94	0.19	25
2018-04-26	2018-03-31	0.63	0.76	0.13	20
2018-01-31	2017-12-31	0.53	0.61	0.08	15
2017-10-25	2017-09-30	0.31	0.53	0.22	70
2017-07-26	2017-06-30	0.35	0.39	0.04	11
2017-04-27	2017-03-31	0.39	0.41	0.02	5
2017-01-25	2016-12-31	0.29	0.35	0.06	20
2016-10-25	2016-09-30	0.18	0.16	-0.02	11
2016-07-27	2016-06-30	0.21	0.24	0.03	14
2016-04-27	2016-03-31	0.29	0.09	-0.2	68
2016-01-27	2015-12-31	0.17	0.17	0.0	0
2015-10-28	2015-09-30	-0.28	-0.13	0.15	53
2015-07-29	2015-06-30	-0.58	-0.54	0.04	6
2015-04-29	2015-03-31	-0.75	-0.83	-0.08	10
2015-01-28	2014-12-31	-0.65	-0.74	-0.09	13
2014-10-28	2014-09-30	-0.62	-0.72	-0.1	16
2014-07-29	2014-06-30	-0.71	-0.68	0.03	4
2014-05-01	2014-03-31	-0.68	-1.0	-0.32	47
2014-01-29	2013-12-31	-0.55	0.19	0.74	134
2013-10-29	2013-09-30	-0.34	-0.54	-0.2	58
2013-07-29	2013-06-30	-0.19	-0.26	-0.07	36
2013-04-30	2013-03-31	-0.18	-0.11	0.07	38
2013-01-29	2012-12-31	-0.08	-0.09	-0.01	12
2012-11-01	2012-09-30	0.2	-0.27	-0.47	235
2012-07-30	2012-06-30	0.58	0.06	-0.52	89
2012-04-26	2012-03-31	0.56	0.43	-0.13	23
2012-02-02	2011-12-31	0.7	0.74	0.04	5
2011-10-27	2011-09-30	0.21	1.02	0.81	385
2011-07-28	2011-06-30	-0.96	-0.85	0.11	11
2011-05-03	2011-03-31	-1.09	-0.87	0.22	20
2011-02-03	2010-12-31	-0.93	-0.9	0.03	3
2010-10-25	2010-09-30	-0.93	-1.04	-0.11	11
2010-07-28	2010-06-30	-0.84	-1.0	-0.16	19
2010-04-21	2010-03-31	-0.8	-0.83	-0.03	3
2010-02-04	2009-12-31	-0.85	-0.85	0.0	0
2009-10-26	2009-09-30	-0.82	-0.84	-0.02	2
2009-08-05	2009-06-30	-0.84	-0.99	-0.15	17
2009-04-16	2009-03-31	-0.82	-1.04	-0.22	26
2009-02-09	2008-12-31	-0.93	-0.96	-0.03	3
2008-10-27	2008-09-30	-0.92	-0.93	-0.01	1
2008-07-31	2008-06-30	-0.57	-0.66	-0.09	15
2008-04-21	2008-03-31	-0.65	-0.72	-0.07	10
2008-02-11	2007-12-31	-0.66	-0.66	0.0	0
2007-10-29	2007-09-30	-0.73	-0.82	-0.09	12
2007-07-24	2007-06-30	-0.69	-0.91	-0.22	31
2007-04-30	2007-03-31	-0.64	-0.64	0.0	0
2007-02-01	2006-12-31	-0.38	-0.22	0.16	42
2006-10-26	2006-09-30	-0.48	-0.46	0.02	4
2006-07-26	2006-06-30	-0.52	-0.72	-0.2	38
2006-04-25	2006-03-31	-0.56	-0.47	0.09	16
2006-02-07	2005-12-31	-0.23	-0.38	-0.15	65
2005-10-26	2005-09-30	-0.47	-0.84	-0.37	78
2005-07-27	2005-06-30	-0.51	-0.5	0.01	1
2005-04-26	2005-03-31	-0.56	-0.56	0.0	0
2005-02-09	2004-12-31	-0.44	-0.54	-0.1	22
2004-10-25	2004-09-30	-0.48	-0.49	-0.01	2
2004-07-26	2004-06-30	-0.51	-0.56	-0.05	9
2004-04-26	2004-03-31	-0.52	-0.52	0.0	0
2004-02-11	2003-12-31	-0.54	-0.51	0.03	5
2003-11-10	2003-09-30	-0.49	-0.58	-0.09	18
2003-07-24	2003-06-30	-0.61	-0.6	0.01	1
2003-04-24	2003-03-31	-0.48	-0.64	-0.16	33
2003-02-04	2002-12-31	-0.4	-0.4	0.0	0
2002-11-04	2002-09-30	-0.3	-0.44	-0.14	46
2002-07-18	2002-06-30	-0.28	-0.28	0.0	0
2002-04-24	2002-03-31	-0.28	-0.29	-0.01	3
2002-02-07	2001-12-31	-0.19	-0.15	0.04	21
2001-10-24	2001-09-30	-0.27	-0.18	0.09	33
2001-07-27	2001-06-30	-0.26	-0.16	0.1	38
2001-04-24	2001-03-31	-0.31	-0.15	0.16	51
2001-02-22	2000-12-31	-0.14	-0.04	0.1	71
2000-10-24	2000-09-30	-0.22	-0.46	-0.24	109
2000-07-26	2000-06-30	0.21	0.22	0.01	4
2000-05-11	2000-03-31	-0.29	-0.31	-0.02	6
2000-02-16	1999-12-31	0.01	0.03	0.02	200
1999-10-27	1999-09-30	-0.25	-0.28	-0.03	12
1999-07-27	1999-06-30	-0.19	-0.21	-0.02	10
1999-04-21	1999-03-31	-0.3	-0.34	-0.04	13
1999-02-25	1998-12-31	-0.21	-0.25	-0.04	19
1998-10-21	1998-09-30	-0.09	-0.04	0.05	55
1998-07-22	1998-06-30	-0.15	-0.19	-0.04	26
1998-04-22	1998-03-31	-0.16	-0.16	0.0	0
1998-02-23	1997-12-31	-0.15	-0.13	0.02	13
1997-10-21	1997-09-30	-0.14	-0.11	0.03	21
1997-07-22	1997-06-30	-0.12	-0.03	0.09	75
1997-04-22	1997-03-31	-0.15	-0.13	0.02	13
1997-02-19	1996-12-31	-0.16	-0.09	0.07	43
1996-10-23	1996-09-30	-0.19	-0.16	0.03	15
1996-07-26	1996-06-30	-0.18	-0.21	-0.03	16
1996-04-25	1996-03-31	-0.17	-0.21	-0.04	23

About Vertex Pharmaceuticals Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Vertex Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Vertex Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Vertex Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'

Please read more on our stock advisor page.

	Last Reported	Projected for Next Year
Retained Earnings	11.7 B	12.2 B
Retained Earnings Total Equity	7.5 B	7.9 B
Earnings Yield	0.03	0.03
Price Earnings Ratio	26.07	27.38
Price Earnings To Growth Ratio	3.13	3.29

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC